Cancer stem cells and individualized therapy

Cancer Genomics and Proteomics

Volumn 4, Issue 3, 2007, Pages 165-174

  Chumsri, Saranya ^a   Phatak, Pornima ^b   Edelman, Martin J ^a   Khakpour, Nazanin ^b   Hamburger, Anne W ^a   Burger, Angelika M ^b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Cancer stem cells; Clonogenicity; Human tumor stem cell assay (HTCA); Review; Side population

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BEVACIZUMAB; CISPLATIN; CYCLOPAMINE; CYTOTOXIC AGENT; FLUOROURACIL; GAMMA SECRETASE INHIBITOR; GRN 163L; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LY 411575; NATURAL PRODUCT; OBLIMERSEN; RETINOIC ACID; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG; VINCA ALKALOID; VORINOSTAT; ZOSUQUIDAR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STEM CELL; CELL ASSAY; CELL ISOLATION; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CLONOGENESIS; COLON CANCER; COLONY FORMATION; CORRELATION ANALYSIS; CYTOLOGY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; INDIVIDUALIZATION; KAPOSI SARCOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; MOLECULAR BIOLOGY; MULTIPLE CANCER; MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVIEW; SOLID TUMOR; THYROID CANCER; TREATMENT RESPONSE;

EID: 34249290073     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Huff CA, Matsui W, Smith BD et al: The paradox of response and survival in cancer therapeutics. Blood 107: 431-434, 2006.
2. McCormick F: New-age drug meets resistance. Nature 412: 281-282, 2001.
3. Al-Hajj M, Becker MW, Wicha M et al: Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14: 43-47, 2004.
4. Jordan CT: Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology. Nat Clin Pract Oncol 2: 224-225, 2005.
5. Abbott A: Cancer: the root of the problem. Nature 442: 742-743, 2006. 6 Wikipedia tfe: Ernest McCulloch, 2006.
6. Becker AJ, Mc CE and Till JE: Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 197: 452-454, 1963.
7. Reya T, Morrison SJ, Clarke MF et al: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
8. Clevers H: Stem cells, asymmetric division and cancer. Nat Genet 37: 1027-1028, 2005.
9. Caussinus E and Gonzalez C: Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster. Nat Genet 37: 1125-1129, 2005.
10. Scharenberg CW, Harkey MA and Torok-Storb B: The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99: 507-512, 2002.
11. Bruce WR and Van Der Gaag H: A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199: 79-80, 1963.
12. Park CH, Bergsagel DE and McCulloch EA: Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 46: 411-422, 1971.
13. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
14. Hope KJ, Jin L and Dick JE: Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5: 738-743, 2004.
15. Liu S, Dontu G and Wicha MS: Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 7: 86-95, 2005.
16. Dontu G, Jackson KW, McNicholas E et al: Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6: R605-615, 2004.
17. Wicha MS, Liu S and Dontu G: Cancer stem cells: an old idea - a paradigm shift. Cancer Res 66: 1883-1890; discussion 1895-1896, 2006.
18. Karhadkar SS, Bova GS, Abdallah N et al: Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431: 707-712, 2004.
19. Gailani MR, Stahle-Backdahl M, Leffell DJ et al: The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 14: 78-81, 1996.
20. Dievart A, Beaulieu N and Jolicoeur P: Involvement of Notchl in the development of mouse mammary tumors. Oncogene 18: 5973-5981, 1999.
21. Olsen CL, Hsu PP, Glienke J et al: Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors. BMC Cancer 4: 43, 2004.
22. Fidler IJ and Hart IR: Biological diversity in metastatic neoplasms: origins and implications. Science 217: 998-1003, 1982.
23. Heppner GH: Tumor heterogeneity. Cancer Res 44: 2259-2265, 1984.
24. Hamburger AW and Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461-463, 1977.
25. Al-Hajj M, Wicha MS, Benito-Hernandez A et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
26. Singh SK, Hawkins C, Clarke ID et al: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
27. Singh SK, Clarke ID, Hide T et al: Cancer stem cells in nervous system tumors. Oncogene 23: 7267-7273, 2004.
28. Matsui W, Huff CA, Wang Q et al: Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336, 2004.
29. Collins AT, Berry PA, Hyde C et al: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951, 2005.
30. Kim CF, Jackson EL, Woolfenden AE et al: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835, 2005.
31. Prince ME, Sivanandan R, Kaczorowski A et al: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978, 2007.
32. Li C, Heidt DG, Dalerba P et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
33. O'Brien CA, Pollett A, Gallinger S et al: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
34. Burger AM: Highlights in experimental therapeutics. Cancer Lett 245: 11-21, 2007.
35. Angstreich GR, Matsui W, Huff CA et al: Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 130: 373-381, 2005.
36. NCCN: Chronic myelogenous leukemia clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 1: 482-500, 2003.
37. O'Brien SG, Guilhot F, Larson RA et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004, 2003.
38. Cortes J, O'Brien S and Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: 2204-2205, 2004.
39. Mauro MJ DB, Kuyl J, Kurilik G and Maziarz RT: Increasing levels of detectable leukemia in imatinib treated CML patients with previously undetectable or very low levels of BCR-ABL. Proc ASCO 22: 569, 2003.
40. Salmon SE, Hamburger AW, Soehnlen B et al: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298: 1321-1327, 1978.
41. Schrag D, Garewal HS, Burstein HJ et al: American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22: 3631-3638, 2004.
42. Buick RN and MacKillop WJ: Measurement of self-renewal in culture of clonogenic cells from human ovarian carcinoma. Br J Cancer 44: 349-355, 1981.
43. Dittrich C, Dittrich E, Sevelda P et al: Clonogenic growth in vitro: an independent biologic prognostic factor in ovarian carcinoma. J Clin Oncol 9: 381-388, 1991.
44. Fiebig HH, Maier A and Burger AM: Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40: 802-820, 2004.
45. Von Hoff DD, Clark GM, Stogdill BJ et al: Prospective clinical trial of a human tumor cloning system. Cancer Res 43: 1926-1931, 1983.
46. Samson DJ, Seidenfeld J, Ziegler K et al: Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22: 3618-3630, 2004.
47. Von Hoff DD, Kronmal R, Salmon SE et al: A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 67: 20-27, 1991.
48. Venezia TA, Merchant AA, Ramos CA et al: Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol 2: e301, 2004.
49. Bao S, Wu Q, McLendon RE et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006.
50. Donnenberg VS and Donnenberg AD: Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45: 872-877, 2005.
51. Sandler A, Gordon M, De Alwis DP et al: A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 10: 3265-3272, 2004.
52. Bedikian AY, Millward M, Pehamberger H et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738-4745, 2006.
53. Badros AZ, Goloubeva O, Rapoport AP et al: Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 23: 4089-4099, 2005.
54. Chen X, Horiuchi A, Kikuchi N et al: Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: It's inhibition leads to growth suppression and apoptosis. Cancer Sci 98: 68-76, 2007.
55. Romer JT, Kimura H, Magdaleno S et al: Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptcl(+/-)p53(-/-) mice. Cancer Cell 6: 229-240, 2004.
56. Shida T, Furuya M, Nikaido T et al: Sonic Hedgehog-Gli1 Signaling Pathway Might Become an Effective Therapeutic Target in Gastrointestinal Neuroendocrine Carcinomas. Cancer Biol Ther 5: 1530-1538, 2006.
57. Lan K, Choudhuri T, Murakami M et al: Intracellular activated Notch1 is critical for proliferation of Kaposi's sarcoma-associated herpesvirus-associated B-lymphoma cell lines in vitro. J Virol 80: 6411-6419, 2006.
58. Pece S, Serresi M, Santolini E et al: Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 167: 215-221, 2004.
59. Nickoloff BJ, Hendrix MJ, Pollock PM et al: Notch and NOXA-related pathways in melanoma cells. J Investig Dermatol Symp Proc 10: 95-104, 2005.
60. Massard C, Deutsch E and Soria JC: Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 17: 1620-1624, 2006.
61. Motohashi T, Aoki H, Chiba K et al: Multipotent cell fate of neural crest-like cells derived from embryonic stem cells. Stem Cells 25: 402-410, 2007.
62. Sanz MA, Lo Coco F, Martin G et al: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96: 1247-1253, 2000.
63. Sanz MA, Martin G, Gonzalez M et al: Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103: 1237-1243, 2004.
64. Sanz MA, Martin G, Rayon C et al: A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 94: 3015-3021, 1999.
65. Mathews V, George B, Lakshmi KM et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107: 2627-2632, 2006.
66. Estey E, Garcia-Manero G, Ferrajoli A et al: Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107: 3469-3473, 2006.
67. Jones LK and Saha V: Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol 130: 489-500, 2005.
68. O'Connor OA: Developing new drugs for the treatment of lymphoma. Eur J Haematol 66 (Suppl): 150-158, 2005.
69. Luong QT, O'Kelly J, Braunstein GD et al: Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12: 5570-5577, 2006.
70. Yaccoby S, Wezeman MJ, Zangari M et al: Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 91: 192-199, 2006.
71. Ocker M, Alajati A, Ganslmayer M et al: The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 131: 385-394, 2005.
72. Xie T and Spradling AC: A niche maintaining germ line stem cells in the Drosophila ovary. Science 290: 328-330, 2000.
73. Hurwitz H, Fehrenbacher L, Novotny W et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
74. Sandler A, Gray R, Perry MC et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
75. Wedam SB, Low JA, Yang SX et al: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24: 769-777, 2006.
76. Miller KD, Chap LI, Holmes FA et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799, 2005.
77. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
78. Yang ZJ and Wechsler-Reya RJ: Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell 11: 3-5, 2007.
79. Sarin KY, Cheung P, Gilison D et al: Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436: 1048-1052, 2005.
80. Hao LY, Armanios M, Strong MA et al: Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 123: 1121-1131, 2005.
81. Burger AM: Telomerase in cancer diagnosis and therapy. BioDrugs 12: 413-422, 1999.
82. Burger AM, Double JA and Newell DR: Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer 33: 638-644, 1997.
83. Schrader M, Burger AM, Muller M et al: Quantification of human telomerase reverse transcriptase mRNA in testicular germ cell tumors by quantitative fluorescence real-time RT-PCR. Oncol Rep 9: 1097-1105, 2002.
84. Cookson JC, Dai F, Smith V et al: Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H- quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol Pharmacol 68: 1551-1558, 2005.
85. Aird RE, Cummings J, Ritchie AA et al: In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer 86: 1652-1657, 2002.
86. Burger AMaHP: Telomerase in germ cell tumours: inhibition of telomerase activity after cisplatin-based therapy. Germ Cell Tumours IV: 73-80, 1998.
87. Lin KK and Goodell MA: Purification of hematopoietic stem cells using the side population. Methods Enzymol 420: 255-264, 2006.
88. Hirschmann-Jax C, Foster AE, Wulf GG et al: A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101: 14228-14233, 2004.
89. Goodell MA, McKinney-Freeman S and Camargo FD: Isolation and characterization of side population cells. Methods Mol Biol 290: 343-352, 2005.
90. Dikmen ZG, Gellert GC, Jackson S et al: In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 65: 7866-7873, 2005.